Eli Lilly and vs Johnson & Johnson: Business Model & Financial Comparison 2026
Eli Lilly and · Healthcare / Drug Manufacturers - General·Johnson & Johnson · Healthcare / Drug Manufacturers - General
Financial Comparison
| Metric | LLYEli Lilly and | JNJJohnson & Johnson |
|---|---|---|
| Market Cap | $896.23B | $587.32B |
| Revenue (TTM) | $65.18B | $94.19B |
| Revenue Growth | 42.6% | 9.1% |
| Gross Margin | 83.0% | 68.1% |
| Operating Margin | 44.9% | 24.0% |
| Net Margin | 31.7% | 28.5% |
| Return on Equity | 101.2% | 35.0% |
| P/E (Trailing) | 43.7x | 22.1x |
| P/E (Forward) | 23.9x | 19.4x |
| Free Cash Flow | $1.95B | $16.63B |
| Cash | $7.27B | $20.10B |
| Total Debt | $43.87B | $49.33B |
Data sourced from Yahoo Finance. Green highlights indicate better performance for that metric. Use the interactive tool for real-time data.
Business Model Comparison
Eli Lilly and
Eli Lilly and Company stands as a leading company in Healthcare. Generating $65.18 billion in annual revenue (growing 42.6% year-over-year) and carrying a market capitalization of $880.04 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Eli Lilly and Company continues to execute on a multi-year strategic vision that balances g…
Full Eli Lilly and analysis →Johnson & Johnson
Johnson & Johnson stands as a leading company in Healthcare. Generating $94.19 billion in annual revenue (growing 9.1% year-over-year) and carrying a market capitalization of $577.48 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Johnson & Johnson continues to execute on a multi-year strategic vision that balances growth inv…
Full Johnson & Johnson analysis →SWOT Analysis Comparison
Strengths
Eli Lilly and
- With a market capitalization of $880.04B, Eli Lilly and Company is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital acces
- Eli Lilly and Company's gross margin of 83.0% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 44.9% demonstrates
- Revenue grew 42.6% year-over-year to $65.18B, indicating strong demand for Eli Lilly and Company's products and services and outperformance relative to many industry peers.
Johnson & Johnson
- With a market capitalization of $577.48B, Johnson & Johnson is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access th
- Johnson & Johnson's gross margin of 68.1% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 24.0% demonstrates dis
- A return on equity of 35.0% demonstrates that Johnson & Johnson generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.
Weaknesses
Eli Lilly and
- With a debt-to-equity ratio of 165.3, Eli Lilly and Company carries significant debt relative to equity. While manageable given its cash flow, elevated leverage limits financial flexibility and increa
Johnson & Johnson
- Johnson & Johnson's debt-to-equity ratio of 60.5 indicates meaningful financial leverage. Total debt stands at $49.33B against $20.10B in cash and equivalents.
- With 138,200 employees globally, Johnson & Johnson faces inherent challenges in agility, decision-making speed, and maintaining a consistent culture across geographies — advantages that smaller, nimbl
Opportunities
Eli Lilly and
- Eli Lilly and Company operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains i
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Eli Lil
- Earnings growth of 51.4% YoY demonstrates Eli Lilly and Company's ability to convert revenue growth into shareholder value. Analysts project continued earnings expansion driven by operating leverage a
Johnson & Johnson
- Johnson & Johnson operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in th
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Johnson
- Earnings growth of 48.6% YoY demonstrates Johnson & Johnson's ability to convert revenue growth into shareholder value. Analysts project continued earnings expansion driven by operating leverage as fi
Threats
Eli Lilly and
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Eli Lilly and Company's revenue is not fully insulated from macroeconomic cycles, and a rece
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Eli Lilly and Compa
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Johnson & Johnson
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Johnson & Johnson's revenue is not fully insulated from macroeconomic cycles, and a recessio
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Johnson & Johnson's
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Compare any 2–4 companies with live data
The interactive comparison tool lets you select any companies, see real-time metrics, and export a side-by-side report.
Open Comparison ToolEli Lilly and vs Johnson & Johnson: FAQ
- Is Eli Lilly and bigger than Johnson & Johnson?
- By market capitalization, Eli Lilly and is larger at $896.23B vs Johnson & Johnson's $587.32B.
- Which has better profit margins — Eli Lilly and or Johnson & Johnson?
- Eli Lilly and has higher net profit margins (31.7%) compared to Johnson & Johnson (28.5%). Gross and operating margins are compared in the table above.
- What sectors do Eli Lilly and and Johnson & Johnson operate in?
- Eli Lilly and operates in the Healthcare sector (Drug Manufacturers - General). Johnson & Johnson operates in the Healthcare sector (Drug Manufacturers - General).
- How does Eli Lilly and's revenue compare to Johnson & Johnson's?
- Eli Lilly and generates $65.18B in annual revenue (TTM) while Johnson & Johnson generates $94.19B. Johnson & Johnson is the larger company by revenue as of 2026.